Please login to the form below

Not currently logged in
Email:
Password:

Vivet Therapeutics

This page shows the latest Vivet Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer goes big on gene therapy with $500m facility spend

Pfizer goes big on gene therapy with $500m facility spend

That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage  haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a  ... It also took a 15% stake in  Vivet Therapeutics and its lead

Latest news

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    a 15% stake in Vivet Therapeutics earlier this year, and in-house mini-dystrophin gene therapy candidate PF-06939926 for Duchenne muscular dystrophy.

  • Catalent preps for complex therapy boom with $1.2bn Paragon buy Catalent preps for complex therapy boom with $1.2bn Paragon buy

    Last month, Pfizer paid around $640m for a 15% stake in Vivet Therapeutics, while Biogen snapped up Nightstar Therapeutics for $800m and Roche acquired Spark Therapeutics in February for $4.3bn. ... And in 2018, Novartis’ bought AveXis for $8.7bn to

  • Pfizer hedges bets on gene therapy deal Pfizer hedges bets on gene therapy deal

    Company not splashing out like Roche's Spark purchase. Pfizer has stopped short of joining 2019's gene therapy buying spree, instead acquiring a 15% of Vivet Therapeutics, and securing an ... Vivet Therapeutics’ lead candidate is VTX-801, a gene

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
...
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...